NabilAdraMD

Oncology • Indianapolis, IN

Genitourinary Oncology

Physician

Join to view full profile

Dr. Adra is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Adra's full profile

Already have an account?

Office
535 Barnhill Drive, RT 455D
Indianapolis, IN 46202
Phone+1 317-278-7728

Education & Training

Indiana University School of MedicineFellowship, Hematology and Medical Oncology, 2014 - 2017
American University of Beirut Faculty of MedicineClass of 2010
Indiana University School of MedicineResidency, Internal Medicine

Certifications & Licensure

IN State Medical License 2017 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma Start of enrollment: 2018 Dec 19
Terminated
Phase 2

Publications & Presentations

PubMed

4 citations
Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.
Jacob J Orme, Fadi Taza, Navonil De Sarkar, Alok K Tewari, Syed Arsalan Naqvi
European Urology Oncology. 2024-08-01
29 citations
Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer
Fadi Taza, Albert E Holler, Wei Fu, Hao Wang, Nabil Adra
JCO Precision Oncology. 2021-07-22
93 citations
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology.
Edward M Schaeffer, Sandy Srinivas, Nabil Adra, Yi An, Daniel Barocas
Journal of the National Comprehensive Cancer Network. 2023-10-01

Lectures

Prognostic value of serum tumor marker (STM) rate of decline during high-dose chemotherapy (HDCT) and peripheral-blood stem-cell transplant (PBSCT) for relapsed germ-c...
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

The Importance of Having Mentors, Both Locally and GloballyMarch 11th, 2020
SWOG Reports Results in Gynecologic Cancer Immunotherapy TrialJanuary 20th, 1970
SUO 2020: Clinical Application for Novel Biomarkers in Testis CancerDecember 6th, 2020

Professional Memberships

American Society of Clinical Oncology - ASCO
Member